Loading...
•
Sep 30, 2024
Agenus Q3 2024 Earnings Report
Agenus reported financial results and provided a corporate update for the third quarter of 2024, highlighting strategic advancements in BOT/BAL development.
Key Takeaways
Agenus reported revenue of $25.1 million and a net loss of $67.2 million for Q3 2024. The company is focused on advancing BOT/BAL, strategic initiatives including asset monetization and operational efficiencies to strengthen its financial position.
Botensilimab (BOT) and balstilimab (BAL) continues to deliver unprecedented outcomes across multiple cancer settings.
BOT/BAL is advancing in 3 ISTs with consistent clinical activity in MSS CRC, a tumor historically resistant to immunotherapy.
Presentations at ESMO2024 highlighted BOT/BAL’s clinical activity advanced sarcomas and other difficult-to-treat cancers, reinforcing its potential to redefine cancer treatment.
Agenus is committed to expanding patient access to BOT/BAL through Compassionate Use and Named Patient Programs.
Agenus
Agenus
Forward Guidance
Agenus is focused on strategic initiatives, including asset monetization and operational efficiencies, to strengthen its financial position and continue driving forward.
Positive Outlook
- BOT/BAL represents one of the most significant advancements in cancer immunotherapy.
- BOT/BAL showing remarkable results in MSS colorectal cancer.
- Operational Efficiencies: Cash outflows have been significantly reduced through focused measures.
- Asset Monetization: Discussions to monetize real estate assets are progressing.
- Agenus is also advancing discussions on a strategic transaction designed to deliver substantial resources.